open access

Vol 4 (2019): Continuous Publishing
CASE REPORTS
Published online: 2019-05-21
Get Citation

Eales’ disease

Ioannis Mallias, Panagiota Petrakogianni
DOI: 10.5603/OJ.2018.0031
·
Ophthalmol J 2019;4:28-30.

open access

Vol 4 (2019): Continuous Publishing
CASE REPORTS
Published online: 2019-05-21

Abstract

This is a case report of a patient diagnosed with Eales’ disease. Characteristics, etiology and symptoms will be described
in this study. Moreover, we will present case of a 61-year-old woman and discuss the clinical features, treatment
plan and its outcome in our patient.

Abstract

This is a case report of a patient diagnosed with Eales’ disease. Characteristics, etiology and symptoms will be described
in this study. Moreover, we will present case of a 61-year-old woman and discuss the clinical features, treatment
plan and its outcome in our patient.

Get Citation

Keywords

Eales’ disease; vitreous haemorrhage; floaters

About this article
Title

Eales’ disease

Journal

Ophthalmology Journal

Issue

Vol 4 (2019): Continuous Publishing

Pages

28-30

Published online

2019-05-21

DOI

10.5603/OJ.2018.0031

Bibliographic record

Ophthalmol J 2019;4:28-30.

Keywords

Eales’ disease
vitreous haemorrhage
floaters

Authors

Ioannis Mallias
Panagiota Petrakogianni

References (12)
  1. Patnaik B, Nagpal P, Namperumalsamy P, et al. Eales disease – clinical features, pathophysiology, ethiopathogenesis. Ophthalmol Clin North Am. 1998; 11(4): 601–617.
  2. Biswas J, Ravi RK, Naryanasamy A, et al. Eales' disease — current concepts in diagnosis and management. J Ophthalmic Inflamm Infect. 2013; 3(1): 11.
  3. Nicolcescu A, Mocanu C, Dinu L, et al. Unilateral Eales’ disease a case report. Rom J Ophthalmol. 2017; 61(2): 144–149.
  4. Gupta SR, Flaxel CJ. The use of a vascular endothelial growth factor inhibitor (ranibizumab) in macular edema due to eales disease. Retin. Cases Brief Rep. 2012; 6(1): 122–124.
  5. Belmokhtar A, Daoudi R. Eales disease: no typical clinical presentation. Pan Afr Med J. 2014; 17: 136.
  6. Jacobiec FA, Albert DM. Atlas of clinical ophthalmology. Saunders, Philadelphia 1996.
  7. Agrawal S, Agrawal J, Agrawal TP. Intravitreal triamcinolone acetonide in Eales disease. Retina. 2006; 26(2): 227–229.
  8. Patwardhan S, Azad R, Shah B, et al. Role of intravitreal bevacizumab in Eales disease with dense vitreous hemorrhage: a prospective randomized control study. Retina. 2011; 31(5): 866–870.
  9. Paine SK, Sen A, Chowdhury IH, et al. Assessment of gelatinase and tumor necrosis factor-α level in the vitreous and serum of patients with Eales disease: role of inflammation-mediated angiogenesis in the pathogenesis of Eales disease. Retina. 2011; 31(7).
  10. Das T, Pathengay A, Hussain N, et al. Eales' disease: diagnosis and management. Eye (Lond). 2010; 24(3): 472–82.
  11. Roy FH, Randall J, Fraunfelder FT. Current Ocular Therapy. Elsevier/Saunders, Philadephia 2008: 624–625.
  12. Fraunfelder FT, Randall J, Roy FH. Current Ocular Therapy. Saunders Company, Philadephia 2000: 609–611.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

VM Media sp. z o.o. VM Group sp.k., Grupa Via Medica, 73 Świętokrzyska St., 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl